Clinical Trial

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Study acronym: MM09-SLIM
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2023 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-29.
Trial Details
NCT Number NCT05641272
Lead Sponsor Inmunotek S.L.
Collaborators: LAT Research, Xolomon Tree S.L.
Conditions Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
Enrollment 90 participants
Start Date 2023-11-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-23